Skip to main content

1 Result(s)

within Yi-kuan Wu Remove this filter

and

  1. No Access

    Article

    Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway

    Most studies regarding the beneficial effect of sulforaphane (SFN) on non-alcoholic fatty liver disease (NAFLD) have focused on nuclear factor E2-related factor 2 (Nrf2). But the molecular mechanisms underlyin...

    Yi-kuan Wu, Zheng-nan Ren, Sheng-long Zhu, Yun-zhou Wu… in Acta Pharmacologica Sinica (2022)